Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04796779 · ClinicalTrials.gov registry record · NA
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
A NA study, sponsored by Marc Breton.
- Completed
- Registry status
- NA
- Development phase
- 102
- Enrollment target
NCT04796779: Completed NA study, sponsored by Marc Breton.
NCT04796779 is a NA study that has completed, run by Marc Breton. The registered enrollment target is 102 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04796779, a NA study, has completed, sponsored by Marc Breton.
- COMPLETED
- Registry status
- NA
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
Primary Outcome
Time in range is the amount of time spent in the target glucose range-between 70 and 180 mg/dL-as measured by CGM
Interventions
- DEVICE Tandem t:slim X2 with Control-IQ Technology Pro
- DEVICE Standard Care (SC)
- DEVICE Tandem t:slim X2 with Control-IQ Technology V1.5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2022-07-31 |
| Phase | NA |
What the finished NCT04796779 record still lists
NCT04796779 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Tandem t:slim X2 with Control-IQ Technology Pro is the first listed.
NCT04796779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04796779 about?
NCT04796779 is a clinical study titled "The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes". The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
What is the current status of trial NCT04796779?
This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2021-04-21. Estimated completion is 2022-07-31.
What interventions are being tested in trial NCT04796779?
The interventions under investigation include: Tandem t:slim X2 with Control-IQ Technology Pro (DEVICE), Standard Care (SC) (DEVICE), Tandem t:slim X2 with Control-IQ Technology V1.5 (DEVICE).
Who is sponsoring clinical trial NCT04796779?
This trial is sponsored by Marc Breton, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04796779's enrollment target sits among peer trials
102 837th of 2000 higher than 1,161 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI